Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD) Initial evidence of disease stabilization was demonstrated for all patients ... 25/04/2023
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy Leriglitazone was well tolerated, and significant benefit was shown through ... 20/01/2023
Leriglitazone’s clinical proof of concept data in Friedreich’s Ataxia published in Neurology Genetics Published data highlights therapeutic potential to treat patients with this ... 29/11/2022
15 Mar 2022 - 20 Mar 2022 AD/PD2022 International Conference on Alzheimer's and Parkinson's Diseases VIRTUAL
17 Oct 2021 - 19 Oct 2021 ANA 2021 - 16th Annual Meeting of the American Neurological Association VIRTUAL
Headquarters https://www.minoryx.com/content/imgs/mail/logo.png Av. Ernest Lluch 32 08302 Mataró (Barcelona) Spain
Belgian R&D Site https://www.minoryx.com/content/imgs/mail/logo.png Ave. Jean Mermoz 32 6041 Gosselies (Charleroi) Belgium